The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Speciality: Oncology


Speaker:

Dr Bhavna Parikh | M.D. Medical Oncologist (Cancer Specialist) Bombay Hospitals

Description:

A warm welcome to all the medical professionals in this insightful session on understanding the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer. The treatment landscape for HR+/HER2- metastatic breast cancer has been revolutionized by the advent of CDK4/6 inhibitors, offering significantly improved outcomes compared to traditional therapies. The landmark PALOMA-2 study, in particular, played a pivotal role in establishing palbociclib in combination with letrozole as a frontline standard of care. This combination has demonstrated a statistically and clinically significant improvement in progression-free survival, delaying disease progression and providing patients with a vital extension of their quality of life. The insights gleaned from PALOMA-2 have guided clinical practice, emphasizing the importance of targeted approaches in this patient population.

Dr. Bhavna Parikh's expertise will illuminate the nuances and broader implications of CDK4/6 inhibition. Her presentation will delve into the comprehensive impact of the PALOMA-2 study, not just on progression-free survival, but also on patient-reported outcomes, safety profiles, and the overall trajectory of HR+/HER2- metastatic breast cancer management. Understanding the detailed efficacy and safety data, as well as real-world evidence, is crucial for optimizing treatment strategies and personalizing care for each patient.

Therefore, get an overall knowledge on the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

2.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

3.

Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US

4.

Targeted Combination Shows Promise in Metastatic Kidney Cancer

5.

Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot